Qualigen Therapeutics Enters Material Definitive Agreement
Ticker: AIXC · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1460702
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Qualigen just signed a big deal, creating a new financial obligation. Details to follow.
AI Summary
On August 21, 2025, Qualigen Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as Ritter Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Carlsbad, California.
Why It Matters
This filing indicates a significant new financial commitment or partnership for Qualigen Therapeutics, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks related to performance, funding, and market conditions.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- August 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Carlsbad, California (location) — Business Address
- Ritter Pharmaceuticals Inc. (company) — Former company name
FAQ
What type of material definitive agreement did Qualigen Therapeutics, Inc. enter into?
The filing states that Qualigen Therapeutics, Inc. entered into a material definitive agreement, but does not specify the exact nature of the agreement in the provided text.
What is the nature of the direct financial obligation created by this agreement?
The filing indicates the creation of a direct financial obligation but does not provide specific details about its terms or amount in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 21, 2025.
What was Qualigen Therapeutics, Inc. formerly known as?
Qualigen Therapeutics, Inc. was formerly known as Ritter Pharmaceuticals Inc.
Where is Qualigen Therapeutics, Inc. headquartered?
Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Filing Stats: 994 words · 4 min read · ~3 pages · Grade level 11.1 · Accepted 2025-08-27 16:30:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share QLGN The Nasdaq Stock Mar
- $1,250,000 — 24, in the original principal amount of $1,250,000 (as previously amended, the "Prior Note
- $4,451,462 — Amended Note has a principal balance of $4,451,462.18, which represents (i) the outstandin
- $216,000 m — eon, and (iii) an additional advance of $216,000 made by the Company to Marizyme on the da
- $1,000 — Preferred Stock at a purchase price of $1,000 per share, for aggregate gross proceeds
- $4.5 m — gregate gross proceeds of approximately $4.5 million, before deducting placement agent
- $4,257,937.50 — expenses, resulting in net proceeds of $4,257,937.50. A pro forma balance sheet as of June
- $2.5 million — total shareholders' equity is more than $2.5 million. Item 9.01. Financial Statements and
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 138KB
- ex99-1.htm (EX-99.1) — 44KB
- 0001641172-25-025702.txt ( ) — 424KB
- qlgn-20250821.xsd (EX-101.SCH) — 3KB
- qlgn-20250821_lab.xml (EX-101.LAB) — 33KB
- qlgn-20250821_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: August 27, 2025 By: /s/ Kevin Richardson II Name: Kevin Richardson II Title: Interim Chief Executive Officer